Evaluation of the tumor histological response after neoadjuvant chemotherapy in advanced gastric adenocarcinoma
DOI:
https://doi.org/10.18050/ucvscientiabiomedica.v4i4.03Keywords:
gastric cancer, neoadjuvant chemotherapy, histological responseAbstract
The objective of the present study was to evaluate the tumor response after neoadjuvant chemotherapy (NAC) in patients diagnosed with advanced gastric adenocarcinoma. A cross-sectional observational analytical study was conducted based on data recorded in the clinical records of patients diagnosed with advanced gastric adenocarcinoma treated with NAC at the Regional Institute of Neoplastic Diseases - Northern IREN during the period from January 2012 to January 2017 To establish the relationship between the associated factors (Age, sex, histological type, primary tumor location, Bormann’s type, degree of cell differentiation, family history and tumor size evaluated by tomography prior to chemotherapy) and the response or not to the Neoadjuvant chemotherapy, bivariate analysis was used. It was found that the tumor size was the only variable statistically related to tumor regression after QNA (OR = 28, p = 0,010) although its 95% CI ranged between 0,92-851,6. It is concluded that there is an association between the tumor size prior to NAC and the tumor response in patients with advanced gastric adenocarcinoma.
References
Hernández E, de Granados G, Williams R. Un enfoque global del cáncer y su curación. Natura Medicatrix 2002; 20 (3): 128 - 139. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=4955674
Dassen A.E. Gastric Cancer Trends and Treatment: Strategies in the Netherlands: Challenges Ahead [Internet]. Erasmus University Rotterdam; 2014. Available from: http://hdl.handle.net/1765/50826
Maskey N, Li K, Hu M, Xu Z, Peng C, Yu F, et al. Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis. Tumor Biol 2014; 35 (12):1837-1843. DOI: https://doi.org/10.1007/s13277-014-2410-2
Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, et al. Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (6): 57 - 63. DOI: https://doi.org/10.1093/annonc/mdt344
Portanova R, Orrego J, Palomino E. Respuesta histológica completa a la neoadyuvancia en cáncer gástrico avanzado. Rev. Chilena de Cirugía 2013; 65 (3): 249 - 254. DOI: http://dx.doi.org/10.4067/S0718-40262013000300009
Selcukbiricik F, Alper A, Kanitez M, Bilici A, Molinas M. Neoadjuvant systemic therapy for patients with gastric cancer: current concepts and outcomes. Journal of Oncological Science 2016; 1:25-30. DOI: http://dx.doi.org/10.1016/j.jons.2015.11.006
Frei E, Miller D, Clark J, Fallon B, Ervin T. Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy. Recent Results in Cancer Research 1986; 103:1-5. DOI: https://doi.org/10.1007/978-3-642-82671-9_1
Wilke H, Preusser P, Fink U, Gunzer U, Meyer H, et al. Preoperative chemotherapy in locally advanced and non resectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7:1318-1326. DOI: http://dx.doi.org/10.1200/JCO.1989.7.9.1318
Xiong B, Cheng Y, Zhang C. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Investigation Journal 2014; 32(6):52-58. DOI: http://dx.doi.org/10.3109/07357907.2014.911877
Fernández G, Durán H, Porrero B. Significado pronóstico de la regresión tumoral histopatológica tras neoadyuvancia del cáncer gástrico: revisión en 57 pacientes. Cir Esp 2014; 92:112-116. Disponible en: https://www.elsevier.es/es-revista-cirugia-espanola-36-congresos-30-congreso-nacional-cirugia-14-sesion-c-esofago-cancer-gastrico-ii-1226-comunicacion-significado-pronostico-regresion-tumoral-histopatologica-13092-pdf
Tian S, Yu J, Kang W, Ma Z, Ye X, Yan C, et al. Effect of neoadjuvant chemotherapy treatment on prognosis of patients with advanced gastric cancer: a retrospective study. Chin Med Sci J 2015; 30(2):84-89. DOI: http://dx.doi.org/10.1016/s1001-9294(15)30017-1
Kodama M, Pereira M, Charruf A, Dias A, Yagi K, et al. Predictors of pathological tumor response in gastric cancer patients after neoadjuvant therapy. Journal of Gastroenterology 2017; 152(5): 131-136. DOI: http://dx.doi.org/10.1200/JCO.2017.35.4_suppl.206
Teng R, Zhou J, Jiang Z, Xu C, Li Z et al. The relationship between Lin28 and the chemotherapy response of gastric cáncer. OncoTargets and Therapy 2013; 6:1341–1345. DOI: http://dx.doi.org/10.2147/OTT.S45705
Jianjun Q, Xiangyang Q. The predictors of response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer Biomark 2016; 17(1):49-54. DOI: http://dx.doi.org/10.3233/CBM-160616
Shahriyar H, Pourzand A, Somi M, Zarrintan S, Javad-Rashid R et al. The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial. International Journal of Surgery 2014; 12:46-51. DOI: http://dx.doi.org/10.1016/j.ijsu.2014.08.349
Mirza A, Naveed A, Hayes S, Formela L, Welch I et al. Assessment of histopathological response in gastric and gastro-oesophageal junction adenocarcinoma following neoadjuvant chemotherapy: which scoring system to use? International Scholarly Research Network 2012; 2012:1-8. DOI: https://doi.org/10.5402/2012/519351
Sun X, Lin J, Ju A. Treatment of Borrmann type IV gastric cancer with a neoadjuvant chemotherapy combination of docetaxel, cisplatin and 5-fluorouracil/leucovorin. Journal of International Medical Research 2011; 39: 2096 – 2102. DOI: https://doi.org/2011;39(6):2096-102
Blackham A, Greenleaf E, Yamamoto M, Hollenbeak C, Gusani N et al. Tumor regression grade in gastric cancer: predictors and impact on outcome. J Surg Oncol 2016; 114(4): 434-439. DOI: https://doi.org/10.1002/jso.24307
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
